Ekso Bionics (NASDAQ:EKSO) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note released on Saturday. The firm issued a hold rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Ekso Bionics in a report on Tuesday, July 30th.

Ekso Bionics Stock Down 15.0 %

Ekso Bionics stock opened at $0.96 on Friday. The company has a current ratio of 2.42, a quick ratio of 1.77 and a debt-to-equity ratio of 0.36. The firm’s fifty day moving average price is $1.11 and its two-hundred day moving average price is $1.15. The firm has a market capitalization of $17.45 million, a price-to-earnings ratio of -0.99 and a beta of 1.45. Ekso Bionics has a 1-year low of $0.83 and a 1-year high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The company had revenue of $4.13 million for the quarter, compared to analyst estimates of $6.00 million. Ekso Bionics had a negative net margin of 68.41% and a negative return on equity of 92.08%. During the same quarter last year, the firm posted ($0.24) EPS. On average, equities research analysts predict that Ekso Bionics will post -0.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC grew its position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.